Precision BioSciences, Inc.
(NASDAQ : DTIL)

( )
DTIL PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
BIIBBiogen, Inc.
0.85%284.671.4%$848.81m
AMGNAmgen, Inc.
0.00%220.861.3%$515.75m
CELGCelgene Corp.
-0.02%110.001.3%$466.68m
GILDGilead Sciences, Inc.
-0.40%64.811.0%$398.75m
VRTXVertex Pharmaceuticals, Inc.
2.34%209.801.9%$313.89m
ILMNIllumina, Inc.
-1.10%302.613.5%$307.88m
REGNRegeneron Pharmaceuticals, Inc.
1.92%344.872.6%$267.68m
EXASEXACT Sciences Corp.
3.55%82.0524.0%$209.78m
ALXNAlexion Pharmaceuticals, Inc.
2.34%108.372.0%$179.80m
SGENSeattle Genetics, Inc.
1.29%114.756.1%$136.96m
BMRNBioMarin Pharmaceutical, Inc.
-0.71%75.044.3%$123.64m
SRPTSarepta Therapeutics, Inc.
0.05%97.4614.6%$115.38m
AAgilent Technologies, Inc.
1.95%78.261.6%$101.36m
NBIXNeurocrine Biosciences, Inc.
2.89%113.055.0%$90.40m
BGNEBeiGene Ltd.
0.94%198.252.1%$88.64m

Company Profile

Precision BioSciences, Inc. is a biotechnology company, which engages in the development of genome editing technologies. It operates through the Therapeutics and Food segments. The Therapeutics segment focuses on the development of products in the field of immuno-oncology and of novel products outside immuno-oncology to treat human diseases. The Food segment applies ARCUS, the company's propriety genome editing platform, to develop food and nutrition products through collaboration agreements with consumer-facing companies. The company was founded by Derek N. Jantz, Jeff Smith, and Matthew R. Kane in January 2006 and is headquartered in Durham, NC.